During the past decade, UF Hepatology Research at CTRB conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 8 clinical trials were completed, i.e. on average, 42.1% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 6 clinical trials were completed. i.e. 120% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UF Hepatology Research at CTRB" #1 sponsor was "Gilead Sciences" with 5 trials, followed by "Intercept Pharmaceuticals" with 3 trials sponsored, "Target PharmaSolutions, Inc." with 3 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored and "Conatus Pharmaceuticals Inc." with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UF Hepatology Research at CTRB" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "University of North Carolina, Chapel Hill" with 1 trials as a collaborator and "Vertex Pharmaceuticals Incorporated" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "UF Hepatology Research at CTRB" are "Nonalcoholic Steatohepatitis" (4 trials), "Hepatitis C" (2 trials), "Hepatitis C Virus Infection" (2 trials), "Hepatitis C, Chronic" (2 trials) and "Hepatocellular Cancer" (2 trials). Many other conditions were trialed in "UF Hepatology Research at CTRB" in a lesser frequency.

Most popular intervention types in "UF Hepatology Research at CTRB" are "Drug" (17 trials), "Other" (2 trials), "Biological" (1 trials), "Device" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "SEL" (3 trials), "Emricasan (5 mg)" (2 trials), "Placebo to match SEL 18 mg" (2 trials) and "Placebo to match SEL 6 mg" (2 trials). Other intervention names were less common.

The vast majority of trials in "UF Hepatology Research at CTRB" are 23 trials for "All" genders.

Currently, there are NaN active trials in "UF Hepatology Research at CTRB". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in UF Hepatology Research at CTRB, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in UF Hepatology Research at CTRB, 0 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".